COMUNICADO: COPD Landmark Trial UPLIFT Proves Tiotropium Sustains Lung Function Improvements Over Four Years and Improves Survival R

    About Boehringer Ingelheim  

    The Boehringer Ingelheim group is one of the world's 20 leading  pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates  globally with 135 affiliates in 47 countries and 39,800 employees. Since it  was founded in 1885, the family-owned company has been committed to  researching, developing, manufacturing and marketing novel products of high  therapeutic value for human and veterinary medicine.  

    In 2007, Boehringer Ingelheim posted net sales of 10.9 billion Euro while  spending one fifth of net sales in its largest business segment Prescription  Medicines on research and development.  

    For more information please visit http://www.boehringer-ingelheim.com  

    About Pfizer Inc  

    Founded in 1849, Pfizer is the world's largest research-based  pharmaceutical company taking new approaches to better health. We discover,  develop, manufacture and deliver quality, safe and effective prescription  medicines to treat and help prevent disease for both people and animals. We  also partner with healthcare providers, governments and local communities  around the world to expand access to our medicines and to provide better  quality health care and health system support. At Pfizer, more than 80,000  colleagues in more than 90 countries work every day to help people stay  happier and healthier longer and to reduce the human and economic burden of  disease worldwide.  

    Webcast and additional media materials  

    To view the UPLIFT Breaking News press briefing at the European Respiratory Society's annual congress in Berlin, Germany, please visit http://www.livecoder.com/clients/bi/20081005_berlin/rmf_dsl_eng.html  

    The briefing will be available for live viewing on Sunday, 5 October  16:00-16:45 (CET) and available on demand from Sunday, 5 October 18:00 (CET).  

    Journalists may want to download additional information here:  http://www.boehringer-ingelheim.com/corporate/news/presspack/uplift_2008/inde x.asp  

    References  

---------------------------------

    (*) Health-related quality of life was evaluated using the Saint George's Respiratory Questionnaire (SGRQ), where a four-point decrease in SGRQ score is considered to be a clinically meaningful improvement in a patient's health-related quality of life.  

---------------------------------

    (1) Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-54.  

    (2) Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease: http://www.goldcopd.com/Guidelineitem.asp?l1=2&l2=1&intId=989 Updated: 2007  

    (3) Source: World Health Report. World Health Organization. Available from URL: http://www.who.int/respiratory/copd/en/  

    (4) World Health Organization. World Health Report 2004. Statistical Annex. Annex table 2 and 3: 120-131.  

    (5) Casaburi R, Kukafka D, Cooper CB, et al. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 2005; 127:809-817.  

    (6) Vincken W, van Noord JA, Greefhorst APM, et al. Improved health outcomes in patients with COPD during 1 year's treatment with tiotropium. Eur Respir J 2002; 19:209-216.  

    (7) Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002; 1:217-224.  

    (8) Celli B, ZuWallack R, Wang S, et al. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003; 124: 1743-1748.  

    (9) O'Donnell DE, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J. 2004 23(6):832-48  

    (10) Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58: 399-404.  

    
    Contact:
    Boehringer Ingelheim GmbH
    
    External Communications
    Ute E Schmidt
    Binger Strasse 173
    55216 Ingelheim am Rhein
    Germany
    Tel.: +49-6132-779-7296
    Head External Communications
    Judith von Gordon
    Binger Strasse 173
    55216 Ingelheim am Rhein
    Germany
    Tel.: +49-6132-773-582
    E: press@boehringer-ingelheim.com
    Pfizer Inc.
    
    Director European Communications
    Oliver Stohlmann
    Tel: +43-152-115-337
    E: oliver.stohlmann@pfizer.com
    Investor Relations
    Jennifer Davis
    Tel: +1-212-733-0717
    E: jennifer.m.davis@pfizer.com

Contact: Boehringer Ingelheim GmbH, External Communications, Ute E Schmidt, Binger Strasse 173, 55216 Ingelheim am Rhein, Germany, Tel.: +49-6132-779-7296; Head External Communications, Judith von Gordon, Binger Strasse 173, 55216 Ingelheim am Rhein, Germany, Tel.: +49-6132-773-582, E: press@boehringer-ingelheim.com; Pfizer Inc., Director European Communications, Oliver Stohlmann, Tel: +43-152-115-337, E: oliver.stohlmann@pfizer.com; Investor Relations, Jennifer Davis, Tel: +1-212-733-0717, E: jennifer.m.davis@pfizer.com